Group 1 - The core point of the article is that Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for its ibuprofen granules, which are intended to relieve mild to moderate pain and fever associated with common colds and influenza [1] - The ibuprofen granules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 edition) [1] - The sales revenue for ibuprofen-related formulations in Chinese public medical institutions is projected to be approximately RMB 4.4 billion in 2024 [1] Group 2 - The approval of this product enhances the variety of ibuprofen formulations offered by the company, providing more medication options for patients [1]

Core Viewpoint - Rongchang Biopharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Vidisicimab (brand name: Aidiqi) for a new indication to treat HER2 low-expressing breast cancer with liver metastasis [1] Group 1 - Vidisicimab is now approved for its fourth indication in China [1] - The drug is indicated for adult patients with unresectable or metastatic HER2 low-expressing breast cancer (IHC 1+ or IHC 2+/ISH-) who have previously received at least one systemic treatment during the metastatic disease stage or have relapsed within 12 months after adjuvant chemotherapy [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which are prescription drugs that assist in the treatment of Parkinson's disease and end-of-dose wearing-off phenomena, classified as a Category B item in the medical insurance directory [1] Group 1 - The approved drug is expected to generate approximately 286 million yuan in sales for public medical institutions in China in 2024 [1] - This approval enhances the company's formulation product portfolio and improves its overall competitiveness [1] - The sales of the drug may be influenced by policies and market factors, leading to uncertainties [1]

Core Viewpoint - The approval of Sugli monoclonal antibody for a new indication in treating stage III non-small cell lung cancer (NSCLC) by the UK Medicines and Healthcare products Regulatory Agency (MHRA) marks a significant milestone for the company, following the earlier approval by the European Commission (EC) [1][2] Group 1: Product Approval and Clinical Significance - Sugli monoclonal antibody has been approved for use in adult patients with unresectable stage III NSCLC who have PD-L1 expression ≥1% and have not progressed after platinum-based chemoradiotherapy [1] - The approval is based on the GEMSTONE-301 clinical trial, which demonstrated statistically significant improvements in progression-free survival (PFS) and clinically meaningful extensions in overall survival (OS) for patients [1] - This marks the second indication approval for Sugli in the UK, expanding its therapeutic applications [1] Group 2: Commercialization and Market Expansion - The commercialization efforts for Sugli have reached over 60 countries and regions, with multiple partnerships established across Europe, the Middle East, Africa, and Latin America [1] - The product has been included in the reimbursement lists of several countries, highlighting its clinical value and economic benefits [2] - The company is actively pursuing registration for additional indications, including gastric cancer and esophageal squamous cell carcinoma [2] Group 3: Leadership Insights - The CEO emphasized that Sugli has become one of the two PD-(L)1 antibodies approved for stage III NSCLC in Europe, covering the entire disease progression from stage III to IV [2] - The Chief Medical Officer noted that the MHRA's approval reinforces the clinical value of Sugli and is expected to enhance its global commercial potential [2] - The company is proud of its clinical development team's efficiency and experience in navigating regulatory frameworks in Europe and the UK [2]

Core Viewpoint - The announcement indicates that the company has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredient, Propranolol Hydrochloride, to be used in marketed formulations [1] Group 1: Product Approval - Propranolol Hydrochloride is now officially registered for use in marketed formulations in China [1] - The drug is primarily used for secondary prevention to reduce mortality from myocardial infarction, hypertension, exertional angina, and to control supraventricular and ventricular arrhythmias [1]

Core Viewpoint - China National Pharmaceutical Group Co., Ltd. announced the approval of fumaric acid volnorelaxin tablets by the National Medical Products Administration, marking a significant step in the company's integrated layout of raw materials and formulations [1] Group 1: Product Approval and Specifications - The approved specifications for the drug are 10mg and 20mg, primarily used for treating reflux esophagitis and eradicating Helicobacter pylori in conjunction with antibiotics [1] - The total investment in the raw material and formulation project for this drug amounts to approximately 12.32 million RMB [1] Group 2: Market Potential and Sales Forecast - According to data from Minet, the estimated sales revenue for this drug in China's three major terminal markets is approximately 774 million RMB in 2024, with sales of about 778 million RMB in the first three quarters of 2025 [1] - Currently, a total of 40 production enterprises, including Tianfang Pharmaceutical, have obtained approval for this drug [1] Group 3: Strategic Implications - The approval is expected to enrich the company's product line and enhance its business layout [1] - Future sales performance may be influenced by uncertainties related to national policies and market conditions [1]

Core Viewpoint - China National Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the registration of Dabigatran Etexilate Capsules, which will enhance the company's product line and development experience in generic drugs [1] Group 1: Product Approval and Specifications - The approved drug includes two specifications: 110mg and 150mg [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Financial and Market Impact - The drug registration application was accepted in May 2024, with a total investment of approximately 28 million RMB [1] - According to data from Minet, the estimated sales revenue for the drug in China's three major terminal markets in 2024 is approximately 571 million RMB [1] Group 3: Competitive Landscape and Future Outlook - Currently, there are 14 manufacturers, including Tianfang Pharmaceutical, that have obtained approval for this drug in China [1] - The company indicated that future sales may be influenced by national policies and market conditions, which could lead to performance that does not meet expectations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關鹽酸普羅帕酮注射液（20ml∶70mg）的藥品生產註 冊批件，屬於化學藥品第3類，視同通過一致性評價，是國內企業第三家獲批。 鹽酸普羅帕酮注射液主要用於需治療的室上性心動過速，如房室交界性心動過速，WPW 綜合 症合併室上性心動過速或陣發性心房顫動，及需治療或致命的室性心動過速。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年一月三十日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...

Core Viewpoint - Haizheng Pharmaceutical's wholly-owned subsidiary, Haizheng Hangzhou, has received FDA approval for the abbreviated new drug application of injectable micafungin, allowing production and sales in the U.S. [1] Group 1: Product Details - The approved drug is available in two specifications: 50mg and 100mg, and is indicated for the treatment and prevention of various candidiasis infections [1] - The global sales forecast for 2024 is approximately $208 million, with the U.S. market contributing about $67.57 million [1] - For the period from January to September 2025, global sales are projected to be around $143 million, with U.S. sales estimated at $46.23 million [1] Group 2: Investment and Financials - The company has invested approximately 17.94 million yuan in this project [1]

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Dextroamphetamine Injection, which is indicated for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved indication for the drug includes restoring blood pressure in acute hypotensive states [1] - The drug can also be used as an auxiliary treatment for cardiac arrest and to maintain blood pressure after cardiac resuscitation [1] - It serves as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1]